caBozantinib in Pre-treated pAtients With Metastatic COlorectal Cancer.

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2019

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

Refractory Colorectal Adenocarcinoma

Interventions

DRUG

Cabozantinib

cabozantinib in patients with refractory mCRC

Trial Locations (1)

"A.O.U dell'Università degli Studi della Campania Luigi Vanvitelli", Napoli

All Listed Sponsors

lead

University of Campania Luigi Vanvitelli

OTHER